Company Description
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally.
The company’s products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples.
In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community.
Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae.
The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets.
OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
| Country | United States |
| Founded | 2000 |
| IPO Date | Nov 12, 1986 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 501 |
| CEO | Carrie Eglinton Manner |
Contact Details
Address: 220 East First Street Bethlehem, Pennsylvania 18015 United States | |
| Phone | 610 882 1820 |
| Website | orasure.com |
Stock Details
| Ticker Symbol | OSUR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001116463 |
| CUSIP Number | 68554V108 |
| ISIN Number | US68554V1089 |
| Employer ID | 36-4370966 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Carrie Eglinton Manner | President, Chief Executive Officer and Director |
| Kenneth J. McGrath | Chief Financial Officer |
| Kathleen Gallagher Weber | Chief Product Officer |
| Michele Anthony | Senior Vice President, Chief Accounting Officer, Controller and Assistant Secretary |
| Rafal Iwasiow Ph.D. | Vice President of Science, Innovation and Technology |
| Jason Michael Plagman | Vice President of Investor Relations |
| Stefano Taucer | General Counsel and Corporate Secretary |
| David A. Rappaport C.F.A. | Senior Vice President Corporate Development, Strategy and Integration |
| Amy Steigerwalt | Senior Vice President of Human Resources |
| Zachary Wert | Senior Vice President of Global Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | SCHEDULE 13G/A | Filing |
| Apr 7, 2025 | ARS | Filing |
| Apr 4, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2025 | SCHEDULE 13G | Filing |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 7, 2025 | 10-K | Annual Report |
| Mar 7, 2025 | 8-K/A | [Amend] Current report |
| Feb 25, 2025 | 8-K | Current Report |
| Jan 7, 2025 | SCHEDULE 13G/A | Filing |